Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP

Citizens JMP raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $38 from $37 and keeps an Outperform rating on the shares. The company reported solid commercial performance in Q2, the analyst tells investors in a research note. The firm says Acadia raised the lower end of the revenue guidance range due to continued Nuplazid strength.